학술논문
1221P Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S1107-S1107
Subject
Language
ISSN
0923-7534